Yipinhong announced on October 8 that its wholly owned subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Eltrombopag Olamine Dry Suspension issued by the National Medical Products Administration. The drug is indicated for adult and pediatric patients aged 6 years and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or other treatments, to raise platelet counts and reduce or prevent bleeding. It is used only in ITP patients whose risk of bleeding is increased due to thrombocytopenia and clinical conditions. The company's approved Eltrombopag Olamine Dry Suspension was filed as a Category 3 chemical drug and is deemed to have passed the consistency evaluation. According to Menet data, sales of Eltrombopag Olamine in China's urban and county-level public hospitals in 2025 were approximately 571 million yuan. In the first half of 2026, Yipinhong achieved revenue of 492 million yuan and net profit attributable to the parent company of 485 million yuan.
Yipinhong Pharmaceutical Co Ltd Class AWholly owned subsidiary received the Drug Registration Certificate from the National Medical Products Administration for Eltrombopag Olamine Dry Suspension, a regulatory approval enabling the drug's sale.
